Close Menu

aneuploidy

LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.

Based on data from more than 6,000 clinical cases, the investigators from Switzerland advocated for an expansion of NIPT to cover additional alterations and associated phenotypes.

Pages